6,248 research outputs found
Detection of Alzheimer's Disease using MRI scans based on Inertia Tensor and Machine Learning
Alzheimer's Disease is a devastating neurological disorder that is
increasingly affecting the elderly population. Early and accurate detection of
Alzheimer's is crucial for providing effective treatment and support for
patients and their families. In this study, we present a novel approach for
detecting four different stages of Alzheimer's disease from MRI scan images
based on inertia tensor analysis and machine learning. From each available MRI
scan image for different classes of Dementia, we first compute a very simple 2
x 2 matrix, using the techniques of forming a moment of inertia tensor, which
is largely used in different physical problems. Using the properties of the
obtained inertia tensor and their eigenvalues, along with some other machine
learning techniques, we were able to significantly classify the different types
of Dementia. This process provides a new and unique approach to identifying and
classifying different types of images using machine learning, with a
classification accuracy of (90%) achieved. Our proposed method not only has the
potential to be more cost-effective than current methods but also provides a
new physical insight into the disease by reducing the dimension of the image
matrix. The results of our study highlight the potential of this approach for
advancing the field of Alzheimer's disease detection and improving patient
outcomes
A comparison of magnetic resonance imaging and neuropsychological examination in the diagnostic distinction of Alzheimer’s disease and behavioral variant frontotemporal dementia
The clinical distinction between Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD) remains challenging and largely dependent on the experience of the clinician. This study investigates whether objective machine learning algorithms using supportive neuroimaging and neuropsychological clinical features can aid the distinction between both diseases. Retrospective neuroimaging and neuropsychological data of 166 participants (54 AD; 55 bvFTD; 57 healthy controls) was analyzed via a Naïve Bayes classification model. A subgroup of patients (n = 22) had pathologically-confirmed diagnoses. Results show that a combination of gray matter atrophy and neuropsychological features allowed a correct classification of 61.47% of cases at clinical presentation. More importantly, there was a clear dissociation between imaging and neuropsychological features, with the latter having the greater diagnostic accuracy (respectively 51.38 vs. 62.39%). These findings indicate that, at presentation, machine learning classification of bvFTD and AD is mostly based on cognitive and not imaging features. This clearly highlights the urgent need to develop better biomarkers for both diseases, but also emphasizes the value of machine learning in determining the predictive diagnostic features in neurodegeneration
Event-Based Modeling with High-Dimensional Imaging Biomarkers for Estimating Spatial Progression of Dementia
Event-based models (EBM) are a class of disease progression models that can
be used to estimate temporal ordering of neuropathological changes from
cross-sectional data. Current EBMs only handle scalar biomarkers, such as
regional volumes, as inputs. However, regional aggregates are a crude summary
of the underlying high-resolution images, potentially limiting the accuracy of
EBM. Therefore, we propose a novel method that exploits high-dimensional
voxel-wise imaging biomarkers: n-dimensional discriminative EBM (nDEBM). nDEBM
is based on an insight that mixture modeling, which is a key element of
conventional EBMs, can be replaced by a more scalable semi-supervised support
vector machine (SVM) approach. This SVM is used to estimate the degree of
abnormality of each region which is then used to obtain subject-specific
disease progression patterns. These patterns are in turn used for estimating
the mean ordering by fitting a generalized Mallows model. In order to validate
the biomarker ordering obtained using nDEBM, we also present a framework for
Simulation of Imaging Biomarkers' Temporal Evolution (SImBioTE) that mimics
neurodegeneration in brain regions. SImBioTE trains variational auto-encoders
(VAE) in different brain regions independently to simulate images at varying
stages of disease progression. We also validate nDEBM clinically using data
from the Alzheimer's Disease Neuroimaging Initiative (ADNI). In both
experiments, nDEBM using high-dimensional features gave better performance than
state-of-the-art EBM methods using regional volume biomarkers. This suggests
that nDEBM is a promising approach for disease progression modeling.Comment: IPMI 201
An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automati c Prognosis of MCI Patients
Alzheimer's disease (AD) and mild cognitive impairment (MCI), continue to be
widely studied. While there is no consensus on whether MCIs actually "convert"
to AD, the more important question is not whether MCIs convert, but what is the
best such definition. We focus on automatic prognostication, nominally using
only a baseline image brain scan, of whether an MCI individual will convert to
AD within a multi-year period following the initial clinical visit. This is in
fact not a traditional supervised learning problem since, in ADNI, there are no
definitive labeled examples of MCI conversion. Prior works have defined MCI
subclasses based on whether or not clinical/cognitive scores such as CDR
significantly change from baseline. There are concerns with these definitions,
however, since e.g. most MCIs (and ADs) do not change from a baseline CDR=0.5,
even while physiological changes may be occurring. These works ignore rich
phenotypical information in an MCI patient's brain scan and labeled AD and
Control examples, in defining conversion. We propose an innovative conversion
definition, wherein an MCI patient is declared to be a converter if any of the
patient's brain scans (at follow-up visits) are classified "AD" by an
(accurately-designed) Control-AD classifier. This novel definition bootstraps
the design of a second classifier, specifically trained to predict whether or
not MCIs will convert. This second classifier thus predicts whether an
AD-Control classifier will predict that a patient has AD. Our results
demonstrate this new definition leads not only to much higher prognostic
accuracy than by-CDR conversion, but also to subpopulations much more
consistent with known AD brain region biomarkers. We also identify key
prognostic region biomarkers, essential for accurately discriminating the
converter and nonconverter groups
- …